Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | WNT1 | P04628 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162140 | 0.89 | WNT1 (0.38) | MLNRMAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20169989 | 0.86 | MAP3K5 (0.47) | TAS2R8MAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20162120 | 0.85 | TAS2R8 (0.49) | TAS2R8MAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20162118 | 0.84 | TAS2R8 (0.36) | TAS2R8MLNRMAP3K5WNT1GSK3B | |
| SCHEMBL20364372 | 0.83 | TAS2R8 (0.41) | TAS2R8MAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20162116 | 0.83 | TAS2R8 (0.39) | TAS2R8MAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20162147 | 0.83 | CYP3A4 (0.43) | RIPK1 | |
| SCHEMBL20162176 | 0.82 | TAS2R8 (0.40) | TAS2R8MAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20330429 | 0.81 | TAS2R8 (0.37) | TAS2R8MAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL20162149 | 0.80 | MAP3K5 (0.34) | MLNRMAP3K5RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| EP-3560494-A1 | DRUG TARGETING CANCER STEM CELL | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885MLNR 4259/4885MAP3K5 3026/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | TAS2R8 2868/4885MLNR 4408/4885MAP3K5 3854/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | TAS2R8 2778/4885MLNR 3939/4885MAP3K5 2768/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885MLNR 4259/4885MAP3K5 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.